8-KRegulation FDExhibits & Filings

BIOGEN INC. 8-K Report, Regulation FD Disclosure (Aug 28, 2007)

Filed August 28, 2007For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on August 28, 2007, primarily to disclose a TYSABRI® (natalizumab) safety update presented at the European Federation of Neurological Societies (EFNS) Congress. The key takeaway for investors is the continued absence of new confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) as of mid-July 2007. This represents a positive development, building upon previous disclosures of no new PML cases through May 2007. Furthermore, the filing provides an update on TYSABRI utilization, indicating approximately 14,000 patients on therapy worldwide (12,900 commercial, 1,000+ clinical trial) as of mid-July 2007. This information, shared alongside the safety update, offers a snapshot of the drug's market penetration and patient adoption following its reintroduction to the U.S. and launch in the EU.

Key Highlights

  • 1No new confirmed cases of PML reported as of mid-July 2007, following prior disclosures of no new cases through May 23, 2007.
  • 2TYSABRI® (natalizumab) safety update presented at the EFNS Congress in Brussels.
  • 3Approximately 14,000 patients worldwide were on TYSABRI therapy as of mid-July 2007.
  • 4Of the total patients, approximately 12,900 were commercial patients and over 1,000 were in clinical trials.
  • 5The report includes Exhibit 99.1, a PowerPoint slide detailing the TYSABRI safety update.
  • 6This information is provided under Regulation FD and is furnished, not filed, meaning it does not inherently subject the company to Section 18 liabilities.
  • 7The utilization update will not be further elaborated on during the EFNS presentation.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose a safety update regarding TYSABRI® (natalizumab) presented at the European Federation of Neurological Societies (EFNS) Congress and to provide an update on patient utilization worldwide.

Yes, the filing indicates that as of mid-July 2007, there have been no new reports of confirmed cases of PML. This is a continuation of the previously reported trend of no new confirmed cases since May 23, 2007.

As of mid-July 2007, approximately 14,000 patients were on TYSABRI therapy globally. This figure includes around 12,900 commercial patients and over 1,000 patients in clinical trials.

For investors, the absence of new confirmed PML cases is a critical positive indicator, addressing a significant safety concern previously associated with TYSABRI. The continued patient utilization figures also suggest ongoing market acceptance and therapeutic use.